BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 10, 2006
View Archived Issues
Takeda presents highlights of previous nine months
Read More
Ferritin synthesis increased by small molecule binding to mRNA
Read More
Protection for gentamicin-evoked nephrotoxicity / News in Context
Read More
Pivotal phase II/III MS trial of MBP-8298 recommended to continue
Read More
Phase I trial investigates APD-668 for type 2 diabetes
Read More
ARYx completes Series E financing
Read More
Phase I SBIR grant supports preclinical work for ALS-886 for stroke
Read More
Oscient acquires expanded rights to ramoplanin
Read More
G2 Therapies and Novo Nordisk to collaborate on antiinflammatory therapies
Read More
Xyotax receives fast track designation for PS2 women with NSCLC
Read More
ReGen Therapeutics to acquire Sciencom
Read More
Open-label phase III extension study planned for Alzhemed in North America
Read More
FDA approves IND for first phase III bladder cancer trial for Bioniche's MCC
Read More
Selective apoptotic agent isolated from an actinomycete
Read More
MF-101 studied in phase II trial for treatment of menopausal symptoms
Read More
Generic name bremelanotide approved for PT-141
Read More
Avrina shows efficacy in eczema
Read More
Alvimopan reduces time to recover GI function following bowel resection surgery
Read More
NRP-290 bioavailability studied in phase I/II trial
Read More
Factor Xa inhibitor shows promise as an antimetastatic agent
Read More
COX-2 inhibitors reduce the risk of breast cancer
Read More
Recent patents disclose novel antiinfective agents
Read More
Novel agents for endocrine-related disorders reported in recent patent literature
Read More
